Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Debt: 2018-2025

  • Dr Reddys Laboratories' Total Debt rose 138.67% to $537.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.3 billion, marking a year-over-year increase of 11.58%. This contributed to the annual value of $537.0 million for FY2025, which is 138.67% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Total Debt stood at $537.0 million for Q1 2025, which was up 138.67% from $225.0 million recorded in Q1 2024.
  • In the past 5 years, Dr Reddys Laboratories' Total Debt ranged from a high of $537.0 million in Q1 2025 and a low of $106.0 million during Q1 2023.
  • Its 3-year average for Total Debt is $289.3 million, with a median of $225.0 million in 2024.
  • Its Total Debt has fluctuated over the past 5 years, first slumped by 75.52% in 2023, then skyrocketed by 138.67% in 2025.
  • Quarterly analysis of 5 years shows Dr Reddys Laboratories' Total Debt stood at $402.0 million in 2021, then grew by 7.71% to $433.0 million in 2022, then slumped by 75.52% to $106.0 million in 2023, then soared by 112.26% to $225.0 million in 2024, then spiked by 138.67% to $537.0 million in 2025.
  • Its Total Debt was $537.0 million in Q1 2025, compared to $225.0 million in Q1 2024 and $106.0 million in Q1 2023.